CSS software could boost Medicare star ratings

Saturday, January 28, 2012 10:24 AM

A new service from Clinical Support Services (CSS) aims to help Medicare plans improve their 2012 star ratings.

The Star Ratings Booster technology platform helps Medicare Advantage and Medicare Prescription Drug Plans support and enhance quality performance ratings. The module enables CSS clinicians, with the support of clients’ pharmacy and medical claims data, to determine a patient’s compliance on select Part C/D measures and generate comprehensive care-enhancing recommendations for the patient, which then may be shared with the patient’s physician and/or pharmacy.

CSS’ web-based module enables pharmacy claims—and other available clinical data—to be uploaded to the client’s patient profiles. The MTMPath module allows CSS clinicians to identify patients who are non-compliant on certain Part C/D measures that would have a negative impact on a plan sponsor’s CMS Star Rating, said CSS president James Notaro, RPh, Ph.D. When a measure is tagged as non-compliant, CSS reaches out to the patient and his/her physician to bring the measure into compliance. This feature gives CSS the potential to improve star ratings measures over time.

Star Ratings Booster has an unlimited patient capacity and was built in accordance with the latest HEDIS-based guidelines.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs